HOTH - Hoth Therapeutics' HT-003 shows encouraging action in preclinical study

Hoth Therapeutics (HOTH) gains 8% in premarket in reaction to new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.Data from series of in vitro experiments showed that Toll-like receptor 2 is significantly inhibited by HT-003, including in the presence of TLR2 agonists."The ability of HT-003 to potently inhibit TLR2 signaling pathway suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by overactive inflammatory responses to bacteria," stated Dr. Zippin, Hoth Senior Scientific Advisor.

For further details see:

Hoth Therapeutics' HT-003 shows encouraging action in preclinical study